Skip to content

Current ratio at other companies

Celcuity logo
CelcuityCELC
12.3×+5.7×
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
6.8×-6.7×
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
21.3×+16.0×
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
15.1×+10.0×
Tango Therapeutics logo
Tango TherapeuticsTNGX
27.4×+21.1×
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
+0.9×

Other financials

Income statement

See full
Revenue$3.0M-60.9%
Operating income-$78.6M+7.4%
Net income-$73.3M+4.9%
EPS (diluted)-$0.41+10.9%

Balance sheet

See full
Cash & equivalents$204.6M+119%
Total debt$31.6M-33.1%
Total equity$642.2M-10.9%
Total assets$699.6M-12.5%

Cash flow

See full
Operating cash flow-$51.1M+30.2%
CapEx$1.0K
Free cash flow-$44.9M+22.5%

Valuation

See full
Market cap$3.46B+300%
Enterprise value$3.29B+304%
P/S324.1×+212×

Profitability

See full
Operating margin-2,776.6%-820pp
Net margin-2,554.1%-745pp
FCF margin-1,536%-429pp

Returns & leverage

See full
Return on equity-40%-4.3pp
Debt / equity0.0×

Where this comes from

Calculated from Relay Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Relay Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relay Therapeutics, Inc.'s current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Relay Therapeutics, Inc.'s current ratio?
Relay Therapeutics, Inc. (RLAY) reported current ratio of 22.1× in Q1 2026.
How has Relay Therapeutics, Inc.'s current ratio changed year-over-year?
Relay Therapeutics, Inc.'s current ratio increased by 10.9% year-over-year, from 20× to 22.1×.
What is the long-term trend for Relay Therapeutics, Inc.'s current ratio?
Over 5 years (2020 to 2025), Relay Therapeutics, Inc.'s current ratio has grown at a -16.7% compound annual growth rate (CAGR), from 56.5× to 22.6×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.